Chris Smith is the CEO of NeoGenomics, Inc. He has been with the company since August 15, 2022, bringing a wealth of experience from his previous role as CEO of Ortho Clinical Diagnostics. Smith also held significant positions at Cochlear...

Chris Smith is the CEO of NeoGenomics, Inc. He has been with the company since August 15, 2022, bringing a wealth of experience from his previous role as CEO of Ortho Clinical Diagnostics. Smith also held significant positions at Cochlear Limited, where he served as CEO and President of Cochlear Americas. His educational background includes a Bachelor of Science degree from Texas A&M University. Under his leadership, NeoGenomics has focused on developing strong business strategies and improving fiscal performance. In 2022, his total compensation was approximately $18.5 million, highlighting the company's commitment to aligning executive pay with performance. Since joining NeoGenomics, Smith has emphasized a customer-first mindset and has implemented a robust succession planning strategy. Interestingly, he received a substantial relocation benefit and an inducement equity award worth around $11.85 million, indicating the company's investment in his leadership. Smith's track record shows a commitment to driving strategic growth and operational improvements.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other NeoGenomics CEOs

N

Chris Smith

Ex-CEO of NeoGenomics

Education

Bachelor of Science degree from Texas A&M University

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

January 1, 1963 - 62 years ago

CEO of NeoGenomics for

2 years 7 months (Aug 2022 - Apr 2025)

Previous Experience

CEO of Ortho Clinical Diagnostics from 2019 to May 2022; key executive leadership positions at Cochlear Limited; CEO in residence at Warburg Pincus; Global Group President at Gyrus Group Plc; various leadership roles at Abbott, KCI, Prism, and Cardinal Health.

Rivals

Competitors/colleagues of Chris Smith

Holdings

See how much did Chris Smith make over time.

As of now, Chris Smith holds a significant position within NeoGenomics, indicated by a hefty equity award package worth about $11.85 million, awarded when he joined the company. This equity package includes both restricted stock and stock options, structured to...

As of now, Chris Smith holds a significant position within NeoGenomics, indicated by a hefty equity award package worth about $11.85 million, awarded when he joined the company. This equity package includes both restricted stock and stock options, structured to vest over several years. His holdings reflect a considerable stake in NeoGenomics, aligning his interests with those of the shareholders. He hasn't completed stock sales recently, which suggests a commitment to the company's long-term growth. This approach can be viewed positively, as it indicates his confidence in the company's future. His wealth tied to the company has fluctuated since his start, emphasizing the importance of stock performance in his overall earnings.

Insider Trading

See recent insider trades of Chris Smith.

QDEL

2,248 shares

QDEL

Jun 6, 2023

Received

NEO

602,219 shares

NEO

Aug 15, 2022

Received

QDEL

34,554 shares

QDEL

May 27, 2022

Received

QDEL

34,554 shares

QDEL

May 27, 2022

Received

Compensation History

See how much did Chris Smith make over time.

Chris Smith’s compensation in 2022 was notable, totaling approximately $18.5 million. This included a base salary of $1 million, a performance bonus of $1.85 million, and other compensation elements. The bonus was largely tied to company performance metrics, showing a clear link between his pay and the company’s success. Interestingly, Smith's overall package was designed to attract top talent, incorporating significant equity awards which amount to around $11.85 million. These awards not only provide a strong financial incentive for Smith to drive company performance but also ensure that his interests align with those of the shareholders. His compensation structure reflects a focus on long-term value creation for the company and its investors, underscoring a strategic approach to leadership.

Year

2022

Total Compensation

$2.86M

Salary

$1.00M

Board Justification

The compensation philosophy is focused on attracting, retaining, and motivating highly skilled management, with a strong emphasis on pay-for-performance.

Bonus

$1.85M

Board Justification

The bonus was based on performance metrics including revenue and adjusted EBITDA, with a corporate performance score of 98% of target, reflecting individual performance and company performance.

Other

$12.11K

Board Justification

Other compensation includes a relocation benefit and retirement plan contributions.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock vested in 2022 as the focus was on the bonus and salary components for the year.

Performance Metrics

Performance metrics included revenue growth, adjusted EBITDA, and strategic critical success factors.

Other NeoGenomics CEOs

Here are other CEOs of NeoGenomics

Tony Zook

CEO of NeoGenomics

April 2025 - Present